Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
03:13:06 EDT Tue 10 Mar 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:EOLS - EVOLUS INC - https://investors.evolus.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
EOLS - Q0.25.29·5.781.55.35-0.18-3.31,322.96,40211,3165.31  5.49  5.15513.81  4.0913Mar 09Mar 0315 min RT 2¢

Recent Trades - Last 10 of 11316
Time ETExPriceChangeVolume
19:56:56Q5.37-0.161
19:00:59Q5.3604-0.16961
18:58:29Q5.36-0.171
16:49:13Q5.3626-0.1674100
16:24:26Q5.3452-0.18481
16:16:01Q5.36-0.173
16:10:04Q5.35-0.181
16:10:04Q5.35-0.181
16:10:04Q5.35-0.181
16:10:04Q5.35-0.181

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-03-03 16:05U:EOLSNews ReleaseEvolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026
2026-02-25 08:00U:EOLSNews ReleaseEvolus to Participate in The Leerink Partners Global Healthcare Conference
2026-02-17 08:00U:EOLSNews ReleaseEvolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026
2026-02-13 16:05U:EOLSNews ReleaseEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-01-09 08:30U:EOLSNews ReleaseEvolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue
2025-11-14 16:05U:EOLSNews ReleaseEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-11-05 16:05U:EOLSNews ReleaseEvolus Reports Third Quarter 2025 Financial Results
2025-10-28 08:00U:EOLSNews ReleaseEvolus to Participate in 2025 Stifel Healthcare Conference
2025-10-22 08:00U:EOLSNews ReleaseEvolus to Report Third Quarter Financial Results on November 5, 2025
2025-10-10 16:05U:EOLSNews ReleaseEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-09-22 09:03U:EOLSNews ReleaseTop Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse(TM) Filler Launch
2025-09-12 17:30U:EOLSNews ReleaseEvolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-09-08 08:30U:EOLSNews ReleaseEvolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer
2025-08-25 08:00U:EOLSNews ReleaseEvolus Announces Positive Data From Pivotal Trial for Evolysse(TM) Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp
2025-08-20 08:00U:EOLSNews ReleaseEvolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse(TM) Sculpt Injectable Hyaluronic Acid Gel Product
2025-08-08 16:05U:EOLSNews ReleaseEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-08-05 16:05U:EOLSNews ReleaseEvolus Reports Second Quarter 2025 Financial Results and Provides Business Updates
2025-07-31 08:05U:EOLSNews ReleaseEvolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau(TM) as a Top Performer Among Leading Neurotoxins
2025-07-22 08:05U:EOLSNews ReleaseEvolus to Report Second Quarter Financial Results on August 5, 2025
2025-07-11 16:05U:EOLSNews ReleaseEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)